On target, off-tumor side effects with GPRC5D-targeting CAR T-cell therapy
| . | GPRC5D CAR T-cell therapy—MCARH109 study32 . | GPRC5D CAR T-cell therapya,33 . | GPRC5D CAR T-cell therapy—OriCAR-017 study34 . | |||
|---|---|---|---|---|---|---|
| . | Grade 1-2 . | Grade 3-4 . | Grade 1-2 . | Grade 3-4 . | Grade 1-2 . | Grade 3-4 . |
| Rash | 18 | 0 | NR | NR | NR | NR |
| Pruritus | 6 | 0 | NR | NR | NR | NR |
| Dry skin | NR | NR | NR | NR | 10 | 0 |
| Nail changes | 65 | 0 | 26 | 0 | 30 | 0 |
| Dry mouth | 6 | 0 | NR | NR | 20 | 0 |
| Dysgeusia | 12 | 0 | NR | NR | NR | NR |
| . | GPRC5D CAR T-cell therapy—MCARH109 study32 . | GPRC5D CAR T-cell therapya,33 . | GPRC5D CAR T-cell therapy—OriCAR-017 study34 . | |||
|---|---|---|---|---|---|---|
| . | Grade 1-2 . | Grade 3-4 . | Grade 1-2 . | Grade 3-4 . | Grade 1-2 . | Grade 3-4 . |
| Rash | 18 | 0 | NR | NR | NR | NR |
| Pruritus | 6 | 0 | NR | NR | NR | NR |
| Dry skin | NR | NR | NR | NR | 10 | 0 |
| Nail changes | 65 | 0 | 26 | 0 | 30 | 0 |
| Dry mouth | 6 | 0 | NR | NR | 20 | 0 |
| Dysgeusia | 12 | 0 | NR | NR | NR | NR |
May be underreported as the median follow-up is 5.2 months, whereas the latest nail changes occurred 6 months after CAR T-cell therapy.